These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 37072259)
1. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain. Kim S; Hwang I; Kim SH; Chung HW; Ji MJ; Moon S; Park HM; Kong G; Hur W Chem Biol Drug Des; 2023 Sep; 102(3):500-513. PubMed ID: 37072259 [TBL] [Abstract][Full Text] [Related]
3. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069 [TBL] [Abstract][Full Text] [Related]
4. NSD3-Induced Methylation of H3K36 Activates NOTCH Signaling to Drive Breast Tumor Initiation and Metastatic Progression. Jeong GY; Park MK; Choi HJ; An HW; Park YU; Choi HJ; Park J; Kim HY; Son T; Lee H; Min KW; Oh YH; Lee JY; Kong G Cancer Res; 2021 Jan; 81(1):77-90. PubMed ID: 32967925 [TBL] [Abstract][Full Text] [Related]
5. Backbone resonance assignments for the SET domain of human methyltransferase NSD3 in complex with its cofactor. Li Y; Ng HQ; Ngo A; Liu S; Tan YW; Kwek PZ; Hung AW; Joy J; Hill J; Keller TH; Kang C Biomol NMR Assign; 2017 Oct; 11(2):225-229. PubMed ID: 28808922 [TBL] [Abstract][Full Text] [Related]
6. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L. Morishita M; Mevius D; di Luccio E BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638 [TBL] [Abstract][Full Text] [Related]
7. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase. Rathert P Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470 [TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase. Sun Y; Zhang Y; Chen X; Yu A; Du W; Huang Y; Wu F; Yu L; Li J; Wen C; Yang H; Shi Q; Geng M; Huang X; Xu S Eur J Med Chem; 2022 Sep; 239():114528. PubMed ID: 35717870 [TBL] [Abstract][Full Text] [Related]
9. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Li W; Tian W; Yuan G; Deng P; Sengupta D; Cheng Z; Cao Y; Ren J; Qin Y; Zhou Y; Jia Y; Gozani O; Patel DJ; Wang Z Nature; 2021 Feb; 590(7846):498-503. PubMed ID: 33361816 [TBL] [Abstract][Full Text] [Related]
10. Histones Methyltransferase NSD3 Inhibits Lung Adenocarcinoma Glycolysis Through Interacting with PPP1CB to Decrease STAT3 Signaling Pathway. Zhou Y; Peng X; Fang C; Peng X; Tang J; Wang Z; Long Y; Chen J; Peng Y; Zhang Z; Zhou Y; Tang J; Liao J; Xiao D; Tao Y; Shi Y; Liu S Adv Sci (Weinh); 2024 Oct; 11(38):e2400381. PubMed ID: 39119928 [TBL] [Abstract][Full Text] [Related]
11. Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs. Piao L; Gao Y; Xu X; Su Y; Wang YD; Zhou J; Gao Y; Fang J; Li Q; Chang S; Kong R Eur J Med Chem; 2024 Mar; 268():116264. PubMed ID: 38412693 [TBL] [Abstract][Full Text] [Related]
12. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. He C; Li F; Zhang J; Wu J; Shi Y J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674 [TBL] [Abstract][Full Text] [Related]
13. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Böttcher J; Dilworth D; Reiser U; Neumüller RA; Schleicher M; Petronczki M; Zeeb M; Mischerikow N; Allali-Hassani A; Szewczyk MM; Li F; Kennedy S; Vedadi M; Barsyte-Lovejoy D; Brown PJ; Huber KVM; Rogers CM; Wells CI; Fedorov O; Rumpel K; Zoephel A; Mayer M; Wunberg T; Böse D; Zahn S; Arnhof H; Berger H; Reiser C; Hörmann A; Krammer T; Corcokovic M; Sharps B; Winkler S; Häring D; Cockcroft XL; Fuchs JE; Müllauer B; Weiss-Puxbaum A; Gerstberger T; Boehmelt G; Vakoc CR; Arrowsmith CH; Pearson M; McConnell DB Nat Chem Biol; 2019 Aug; 15(8):822-829. PubMed ID: 31285596 [TBL] [Abstract][Full Text] [Related]
14. Prospect of targeting lysine methyltransferase NSD3 for tumor therapy. Li D; Tian T; Ko CN; Yang C Pharmacol Res; 2023 Aug; 194():106839. PubMed ID: 37400043 [TBL] [Abstract][Full Text] [Related]
15. NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions. Nuñez Y; Vera S; Baeza V; Gonzalez-Pecchi V Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256018 [TBL] [Abstract][Full Text] [Related]
16. [NSD3 suppresses LPS-triggered TNF-α production via promoting the dimethylation of histone H3K36 in macrophages]. Liu Z; Cheng Q; Yang L; Sun Y Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):481-487. PubMed ID: 30236198 [TBL] [Abstract][Full Text] [Related]
17. NSD3: Advances in cancer therapeutic potential and inhibitors research. Xiu S; Chi X; Jia Z; Shi C; Zhang X; Li Q; Gao T; Zhang L; Liu Z Eur J Med Chem; 2023 Aug; 256():115440. PubMed ID: 37182335 [TBL] [Abstract][Full Text] [Related]
18. Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction. Xiong J; Pecchi VG; Qui M; Ivanov AA; Mo X; Niu Q; Chen X; Fu H; Du Y Assay Drug Dev Technol; 2018; 16(2):96-106. PubMed ID: 29634317 [TBL] [Abstract][Full Text] [Related]
19. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Topchu I; Pangeni RP; Bychkov I; Miller SA; Izumchenko E; Yu J; Golemis E; Karanicolas J; Boumber Y Cell Mol Life Sci; 2022 May; 79(6):285. PubMed ID: 35532818 [TBL] [Abstract][Full Text] [Related]
20. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Rahman S; Sowa ME; Ottinger M; Smith JA; Shi Y; Harper JW; Howley PM Mol Cell Biol; 2011 Jul; 31(13):2641-52. PubMed ID: 21555454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]